What's Happening?
Biogen Inc. has successfully completed its acquisition of Apellis Pharmaceuticals, Inc., a company known for its advancements in treatments for complement-driven diseases. This acquisition, finalized on May 14, 2026, positions Apellis as a wholly owned
subsidiary of Biogen. The deal includes the integration of two key products, EMPAVELI® and SYFOVRE®, which are expected to enhance Biogen's growth prospects and expand its reach into nephrology. These products generated $689 million in net revenue in 2025. The acquisition is anticipated to be accretive to Biogen's non-GAAP diluted EPS by 2027, with updated financial guidance to be provided in the upcoming Q2 earnings report. The transaction involved a tender offer of $41 per share in cash, along with contingent value rights, which was accepted by 82.4% of Apellis shareholders.
Why It's Important?
The acquisition of Apellis Pharmaceuticals by Biogen is significant as it strengthens Biogen's position in the biotechnology sector, particularly in the treatment of rare and serious diseases. By acquiring Apellis, Biogen gains access to innovative therapies that address unmet medical needs, such as geographic atrophy and C3 glomerulopathy. This move not only diversifies Biogen's product portfolio but also enhances its capabilities in nephrology, a field with substantial growth potential. The integration of Apellis's products is expected to drive revenue growth and improve Biogen's earnings per share, benefiting shareholders and potentially leading to advancements in patient care. The acquisition also underscores Biogen's strategic focus on expanding its therapeutic areas and leveraging its expertise in biotechnology to deliver impactful treatments.
What's Next?
Following the acquisition, Biogen plans to integrate Apellis's operations and leverage its established nephrology infrastructure to accelerate the launch of new treatments, such as felzartamab, which is in Phase 3 trials for antibody-mediated rejection in kidney transplant patients. Biogen will provide updated financial guidance in its Q2 earnings report, reflecting the impact of the acquisition. The company will also focus on achieving the sales thresholds required for contingent value rights payments, which could further enhance shareholder value. As Biogen integrates Apellis, it will likely continue to explore additional opportunities for growth and innovation in the biotechnology sector.
